The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
What were the long-term outcomes of fixed-duration mosunetuzumab in B-NHL?
Featured:
L. Elizabeth Budde
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
Question 1 of 2
Which antigen on malignant B cells does mosunetuzumab target?
A
B
C
D
The Lymphoma Hub was pleased to speak to Elizabeth Budde, City of Hope Comprehensive Cancer Center, Duarte, US. We asked about the long-term outcomes of fixed-duration mosunetuzumab in B-cell non-Hodgkin lymphoma (B-NHL).
What were the long-term outcomes of fixed-duration mosunetuzumab in B-NHL?
In this interview, Dr Budde discusses the long-term outcomes of treatment with fixed-duration mosunetuzumab in patients with B-NHL, with a focus on follicular lymphoma. Budde reviews the efficacy and safety data from the extended follow-up of the phase II GO29781 (NCT02500407) dose-escalation study, addressing duration of response, remission, overall survival (OS), and CD19-positive B-cell recovery. Budde also describes the characteristics of mosunetuzumab, including its outpatient administration and minimal steroid use.
Key points and data from GO29781*
- Mosunetuzumab is a CD20/CD3 bispecific T-cell engager that directs T cells to target malignant B cells, administered in an outpatient setting with minimal steroid use.
- Mosunetuzumab was administered at a fixed duration of 8 cycles, with each cycle lasting 21 days.
- At a median follow-up of 37.4 months, the median duration of response among 70 responders was 36 months, while the median duration of complete response was not reached.
- The 30-month remission rate was 72.4%.
- The estimated 36-month OS rate was 82.4%, with median OS not reached.
- The median time to CD19-positive B-cell recovery following treatment was 18.4 months.
- No new safety concerns were identified in this extended follow-up.
- Patients retreated with mosunetuzumab post an initial response to mosunetuzumab were also analyzed and high response rates were observed with retreatment.
- These findings support the continued use of mosunetuzumab as a fixed-duration treatment for patients with relapsed or refractory follicular lymphoma in the outpatient setting.
- The data include patients with high-risk disease, such as those refractory to previous therapies or with high-risk molecular features, including the TP53 mutation.
*Data submitted for publication.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
